Mucosal vaccine delivery: Is M cell-targeted delivery effective in the mucosal lumen?

Expert Opinion on Drug Delivery

Volumn 10, Issue 2, 2013, Pages 157-161

  Lo, David D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE; VACCINE;

CELL INTERACTION; CELL TYPE; DRUG DELIVERY DEVICE; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; INTRAGASTRIC DRUG ADMINISTRATION; MICROFOLD CELL; NONHUMAN; POLIOMYELITIS; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; TYPHOID FEVER;

EID: 84872741836     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.740008     Document Type: Review

References (29)

1. Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 2012;14:17-46
2. Asanuma H, Aizawa C, Kurata T, Tamura S. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine 1998;16:1257-62 (Pubitemid 28308405)
3. Craig SW, Cebra JJ. Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit. J. Exp Med 1971;134:188-200
4. Wu HY, Nguyen HH, Russell MW. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand J Immunol 1997;46:506-13 (Pubitemid 27497638)
5. Shikina T, Hiroi T, Iwatani K, et al. IgA class switch occurs in the organized nasopharynx-and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J Immunol 2004;172:6259-64 (Pubitemid 38621232)
6. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996;86:345-8 (Pubitemid 26272074)
7. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6:148-58 (Pubitemid 43361590)
8. Clark MA, Hirst BH, Jepson MA. M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect Immun 1998;66:1237-43 (Pubitemid 28101170)
9. Fotopoulos G, Harari A, Michetti P, et al. Transepithelial transport of HIV-1 by M cells is receptor-mediated. Proc Natl Acad Sci USA 2002;99:9410-14 (Pubitemid 34764627)
10. Hase K, Kawano K, Nochi T, et al. Uptake through glycoprotein 2 of FimH (+) bacteria by M cells initiates mucosal immune response. Nature 2009;462:226-30
11. Jensen VB, Harty JT, Jones BD. Interactions of the invasive pathogens Salmonella typhimurium, Listeria monocytogenes, and Shigella flexneri with M cells and murine Peyer's patches. Infect Immun 1998;66:3758-66 (Pubitemid 28347834)
12. Martinoli C, Chiavelli A, Rescigno M. Entry route of Salmonella typhimurium directs the type of induced immune response. Immunity 2007;27:975-84. (Pubitemid 50013977)
13. Nakato G, Hase K, Suzuki M, et al. Cutting edge: Brucella abortus exploits a cellular prion protein on intestinal M cells as an invasive receptor. J Immunol 2012;189:1540-4
14. Wolf JL, Rubin DH, Finberg R, et al. Intestinal M cells: a pathway for entry of reovirus into the host. Science 1981;212:471-2 (Pubitemid 11041943)
15. Glomski IJ, Piris-Gimenez A, Huerre M, et al. Primary involvement of pharynx and peyer's patch in inhalational and intestinal anthrax. PLoS Pathog 2007;3:e76
16. Garinot M, Fiévez V, Pourcelle V, et al. Gylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007;120:195-204 (Pubitemid 47061488)
17. Nochi T, Yuki Y, Matsumura A, et al. A novel M cell-specific carbohydratetargeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 2007;204:2789-96 (Pubitemid 350179549)
18. Rynda A, Maddaloni M, Mierzejewska D, et al. Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J Immunol 2008;180:5187-200
19. Suzuki H, Sekine S, Kataoka K, et al. Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology 2008;135:917-25
20. Wang X, Kochetkova I, Haddad A, et al. Transgene vaccination using Ulex europaeus agglutinin I (UEA-I) for targeted mucosal immunization against HIV-1 envelope. Vaccine 2005;23:3836-42 (Pubitemid 40704748)
21. Wu Y, Wang X, Csencsits KL, et al. M cell-targeted DNA vaccination. Proc Natl Acad Sci USA 2001;98:9318-23 (Pubitemid 32743914)
22. Rajapaksa TE, Stover-Hamer M, Fernandez X, et al. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release 2010;142:196-205
23. Rajapaksa TE, Bennett KM, Hamer M, et al. Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength. J Biol Chem 2010;285:23739-46
24. Lo DD, Ling J, Eckelhoefer AH. M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotechnol 2012;12:7
25. Frey A, Giannasca KT, Weltzin R, et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996;184:1045-59 (Pubitemid 26313562)
26. Lai SK, O'Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007;104:1482-7 (Pubitemid 46214616)
27. Lai SK, Wang Y-Y, Hida K, et al. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci USA 2010;107:598-603
28. Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 2004;1:141-63 (Pubitemid 40297962)
29. Shakweh M, Besnard M, Nicolas V, Fattal E. Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur J Pharm Biopharm 2005;61:1-13 (Pubitemid 41096683)